Diagnostic Value of Ischemia-Modified Albumin in Terms of Acute Coronary Syndromes in Chronic Renal Patients Admitted to Emergency Department with Chest Pain and/or Equivalent Symptoms

Year 2022, Volume: 3 Issue: 1, 70 - 78, 12.03.2022

İrfan Gökçek , Bedriye Müge Sönmez , Çiğdem Yücel , Mebrure Beyza Gökçek , Fatih Alper Ayyıldız

https://doi.org/10.48176/esmj.2022.51

Abstract

Introduction: This study aimed to reveal the diagnostic value of Ischemia-Modified Albumin (IMA) in terms of acute coronary syndromes in chronic renal patients admitted to emergency department with chest pain and equivalent symptoms.
Methods: Our study is a descriptive cross-sectional research and included 125 chronic renal patients admitted to emergency department with chest pain and/or equivalent symptoms and 96 healthy volunteers as the control group.
Results: In our study, acute coronary syndrome (ACS) was detected in 12 (9.6%) of the patients. Mean IMA level was 0.72±0.17 absorbance units (ABSU) in the group with Chronic renal disease (CRD)+ACS, 0.71±0.16 ABSU in patients with CRD but without ACS, and 0.47±0.14 ABSU in the control group. A statistically significant difference was found between the groups. While no difference between chronic renal patients in whom ACS developed and chronic renal patients in whom ACS did not develop was recorded in terms of IMA. IMA value of both patients with CRD and chronic renal patients in whom ACS developed was significantly higher than that of the healthy control group. In our study, no correlation was found between troponin levels and IMA.
Conclusion: IMA level increases in both CRD and ACS. Therefore, it was determined that IMA level did not significantly increase although ACS developed depending on already high IMA level in patients with CRD. We believe IMA cannot be safely used for the diagnosis of ACS in patients with CRD due to the low specificity rate and absence of an optimal threshold value.

Keywords

Ischemia Modified Albumin, Acute Coronary Syndrome, Chronic Renal Disease

Göğüs Ağrısı ve/veya Anjinal Eşdeğer Semptomlarla Acil Servise Başvuran Kronik Böbrek Hastalarında İskemi-Modifiye Albüminin Akut Koroner Sendromlar Açısından Tanısal Değeri

Abstract

Giriş: Bu çalışmanın amacı; göğüs ağrısı ve eşdeğer semptomlar ile acil servise başvuran kronik böbrek hastalarında İMA’nın akut koroner sendromlar açısından tanısal değerliliğini ortaya koymaktır.
Yöntemler: Çalışmamız tanımlayıcı kesitsel tipte bir araştırma olup; göğüs ağrısı ve/veya eşdeğer semptomlar ile acil servise başvuran 125 kronik böbrek hastası ve kontrol grubu olarak da 96 sağlıklı gönüllü çalışmaya dahil edilmiştir.
Bulgular: Çalışmamızda hastaların 12’sinde (%9,6) AKS saptandı. Çalışmamızda KBH+AKS’li grubun İMA düzeyi ortalaması 0,72±0,17 ABSUs, KBH’li olup AKS’si olmayan hastaların İMA düzeyi ortalaması 0,71±0,16 ABSUs ve kontrol grubunun İMA düzeyi ortalaması 0,47±0,14 ABSUs olduğu saptandı. Gruplar arasında istatistiksel olarak anlamlı farklılık saptandı (p<0,05). AKS gelişen kronik böbrek hastaları ve AKS gelişmeyen kronik böbrek hastaları arasında İMA açısından fark saptanmazken (p: 0,859); hem KBH’li hastaların hem de AKS gelişen kronik böbrek hastalarının İMA değeri sağlıklı kontrol grubuna göre anlamlı olarak yüksekti (p<0,05). Çalışmamızda troponin düzeyleri ve İMA arasında korelasyona rastlanmadı (p>0,05). KBH’li hastalarda İMA için EAA 0,877 cm2 pozitif kabul edildiği 0,05 ABSUs, değerinde sensitivite %61,5 ve spesifite % 89,6; AKS’li hastalarda İMA için EAA 0,876 cm2 pozitif kabul edildiği 0,05 ABSUs, değerinde sensitivite %83,3 ve spesifite % 61,5; KBH’li hastalarda AKS gelişimindeki İMA için EAA 0,524 cm2 pozitif kabul edildiği 0,05 ABSUs, değerinde sensitivite %83,3 ve spesifite % 9,7 olarak saptandı.
Sonuç: Gerek KBH’de gerekse AKS’de İMA düzeyi artmaktadır. Bu nedenle; KBH’li olgularda İMA’nın halihazırda yüksek olmasına bağlı olarak, AKS gelişmiş olsa dahi İMA düzeyinin anlamlı olarak yükselmediği belirlendi. Gerek spesifitenin düşük olması, gerek optimal eşik değerin bulunamamış olması nedeni ile KBH’li hastalarda; İMA’nın AKS tanısı için güvenli olarak kullanılamayacağı kanısındayız.

Keywords

İskemi-modifiye albümin, akut koroner sendrom, kronik böbrek hastalığı

References

• 1- Özen M, Serinken M, Yılmaz A, ve ark. Acil Servise Başvuran Akut Koroner Sendrom Tanılı Hastaların Sosyodemografik ve Klinik Özellikleri. Türkiye Acil Tıp Dergisi. 2012;12(3);113-117
• 2- Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl JMed. 2003;348(10):933-40.
• 3- Thygesen K, Alpert JS, White HD, Jaffe AS, et al. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50(22):2173-95.
• 4- Sgarbossa EB, Pinski SL, Gates KB, et al. Early electrocardiographic diagnosis of acute myocardial infarction in the presence of ventricular paced rhythm. GUSTO-I investigators. Am J Cardiol. 1996;77(5):423-4
• 5- Duygu E, Kahraman N, Pehlivanoğlu S, ve ark. Akut Koroner Sendrom Dışı Olaylarda Kardiyak Troponin Yüksekliğinin Klinik Önemi. Türk Kardiyol Dern Arş. 2004;32(8):571-80.
• 6- Balamuthusamy S, Khosla S, Meka S, et al. Clinical utility of cardiac troponin I in the diagnosis of acute coronary syndrome in patients with renal failure. Am J Ther. 2007;14(4):356-60.
• 7- Roy D, Quiles J, Sharma R, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem. 2004;50(9):1656-60
• 8- Turedi S, Gunduz A, Mentese A, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med. 2007;25(7):7703.
• 9- Bar–Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report1. J Emerg Med. 2000;19(4):311-5.
• 10- Lau J, Ioannidis JP, Balk EM, et al. Diagnosing acute cardiac ischemia in the emergency department: a systematic review of the accuracy and clinical effect of current technologies. Ann Emerg Med. 2001;37(5):453-60.
• 11- Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. G Ital Cardiol (rome). 2008;9:209-22.
• 12- C.M. Nagesh, Ambuj Roy. Role of biomarkers in risk stratification of acute coronary syndrome. Indian J Med Res. 2010 Nov; 132(5): 627–633.
• 13- Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228.
• 14- Chawla R, Goyal N, Calton R, et al. Ischemia modified albumin: a novel marker for acute coronary syndrome. Indian J Clin Biochem. 2006;21(1):77-82.
• 15- Sbarouni E, Georgiadou P, Kremastinos DT, et al. Ischemia modified albumin: is this marker of ischemia ready for prime time use. Hellenic J Cardiol. 2008;49(4):260-6.
• 16- McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312(3):159-63.
• 17- Berenshtein E, Mayer B, Goldberg C, et al. M. Patterns of mobilization of copper and iron following myocardial ischemia: possible predictive criteria for tissue injury. J Mol Cell Cardiol. 1997;29(11):3025-34.
• 18- Christenson RH, Duh SH, Sanhai WR, et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem. 2001;47(3):464-70.
• 19- Sinha M, Roy D, Gaze D, et al. Role of “Ischemia modified albumin”, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J. 2004;21(1):29-34.
• 20- Ozdem S, Çete Y, Donmez L, ve ark. Sağlıklı yetişkinlerde ve akut koroner sendromlu hastalarda serum iskemi modifiye albumin (İMA) düzeyleri. Turk J Emerg Med. 2005;5:169-74.
• 21- Roy D, Quiles J, Aldama G, et al. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol. 2004;97(2):297-301.
• 22- Yaylalı Ç. Acil Servise Başvuru Anında Troponin I Seviyesi Normal Olan Göğüs Ağrılı Hastalarda Kalp Tipi Yağ Asidi Bağlayıcı Protein ve İskemi Modifiye Albuminin Kombine Kullanımının Tanısal Değeri. (Uzmanlık tezi) Konya 2010.
• 23- Çevik E, Yılmaz BK, Acar YA, ve ark. Bazı Erken Kardiyak Belirteçlerin (Miyoglobin, İMA ve Copeptin) Tanısal Performansının STYME Hastalarında Değerlendirilmesi. Turk J Emerg Med. 2013;13(3):127-32.
• 24- Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis. 2006;47(3):493-502.
• 25- Guven R. Diagnostic Utility of Ischemic Modified Albumin in Young Adult Patients with Acute Coronary Syndrome. J Clin Anal Med. 2016;7(5):690-4.
• 26- Turedi S, Cinar O, Yavuz I, et al. Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J Nephrol. 2010;23(3):335-40.
• 27- Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of kidney disease and hypertension (AASK) Trial. Am J Kidney Dis. 2006;48(5):739-51.
• 28- Sharma R, Gaze DC, Pellerin D, et al. Evaluation of ischaemia-modified albumin as a marker of myocardial ischaemia in end-stage renal disease. Clin Sci. 2007;113(1):25-32.
• 29- Nelson J, Liao D, Sharrett AR, et al. Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000;151(5):468-77.
• 30- Kinnunen S, Karhapaa P, Juutilainen A, et al. Secular Trends in Infection-Related Mortality after Kidney Transplantation. Clin J Am Soc Nephrol. 2018 May 7;13(5):755-762.
• 31- Anees M, Hussain Y, Ibrahim M, et al. Outcome of Chronic Kidney Disease Patients on the Basis of Referral to Nephrologist: A One-Year Follow-up Study. J Coll Physicians Surg Pak 2018;28(4):304-7.
• 32- Olesen KK, Madsen M, Egholm G, et al. Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment. Diabetes Care. 2017;40(8):1103-10.
• 33- Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers. 2008;24(6):311-7.
• 34- Kiraz A. Diabetik ve nondiabetic kronik böbrek yetmezlikli hastalarda iskemi modifiye albumin düzeyleri: Selçuk Üniversitesi Sağlık Bilimleri Enstitüsü (UzmanlıkTezi) Konya 2010; 2010.
• 35- Altuntaş E, Bengü AŞ, Kiraz ZK, ve ark. Yeni Tespit Esansiyel Hipertansiyon ile Sigara, Asimetrik Dimetil Arginin ve İskemik Modifiye Albumin Arasındaki İlişki. Istanb Med J. 2017;18(2):86-90.
• 36- Keating L, Benger J, Beetham R, et al. The PRIMA study: presentation ischaemia-modified albumin in the emergency department. Emerg Med J. 2006;23(10):764-8.